During the past decade, Universitätsklinikum Regensburg; Klinik und Poliklinik für Innere Medizin II, Pneumologie conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 5 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 2 clinical trials were completed. i.e. 200% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Universitätsklinikum Regensburg; Klinik und Poliklinik für Innere Medizin II, Pneumologie" #1 sponsor was "Hoffmann-La Roche" with 4 trials, followed by "Actelion" with 2 trials sponsored, "Genentech, Inc." with 1 trials sponsored, "Johannes Gutenberg University Mainz" with 1 trials sponsored and "Pfizer" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Universitätsklinikum Regensburg; Klinik und Poliklinik für Innere Medizin II, Pneumologie" #1 collaborator was "German Federal Ministry of Education and Research" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Universitätsklinikum Regensburg; Klinik und Poliklinik für Innere Medizin II, Pneumologie" are "Non-Small Cell Lung Cancer" (3 trials), "Pulmonary Arterial Hypertension" (2 trials), "Asthma" (1 trials), "Carcinoma, Non-Small-Cell Lung" (1 trials) and "IgA Nephropathy" (1 trials). Many other conditions were trialed in "Universitätsklinikum Regensburg; Klinik und Poliklinik für Innere Medizin II, Pneumologie" in a lesser frequency.

Most popular intervention types in "Universitätsklinikum Regensburg; Klinik und Poliklinik für Innere Medizin II, Pneumologie" are "Drug" (10 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (3 trials), "Docetaxel" (2 trials), "Placebo" (2 trials), "Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody" (1 trials) and "Crizotinib" (1 trials). Other intervention names were less common.

The vast majority of trials in "Universitätsklinikum Regensburg; Klinik und Poliklinik für Innere Medizin II, Pneumologie" are 10 trials for "All" genders.

Currently, there are NaN active trials in "Universitätsklinikum Regensburg; Klinik und Poliklinik für Innere Medizin II, Pneumologie". undefined are not yet recruiting, undefined are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Universitätsklinikum Regensburg; Klinik und Poliklinik für Innere Medizin II, Pneumologie, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Universitätsklinikum Regensburg; Klinik und Poliklinik für Innere Medizin II, Pneumologie, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".